Abstract
Emergence of systems biology is expected to have a large
impact on pharmaceutical R&D. Systems approaches will be
useful in characterization of complex responses to
therapeutic interventions in non-clinical studies and
discovery research, as well as for providing better
predictive models for drug safety and efficacy in
clinical phases. Specific examples from clinical studies
of lipid lowering drugs, schizophrenia, and type 1
diabetes will be used to illustrate the potential of
systems biology in pharmaceutical R&D.
| Original language | English |
|---|---|
| Pages (from-to) | S23 |
| Journal | European Journal of Pharmaceutical Sciences |
| Volume | 34 |
| Issue number | 1 supplement 9 |
| DOIs | |
| Publication status | Published - 2008 |
| MoE publication type | B3 Non-refereed article in conference proceedings |
| Event | 19th Helsinki Drug Research 2008 - Helsinki, Finland Duration: 9 Jun 2008 → 11 Jun 2008 |
Keywords
- systems biology
- drug discovery
- drugs
- drug safety
- pharmaceutical
- pharmaceutical industry